Locally advanced (laUC) or metastatic urothelial carcinoma (mUC) is an aggressive form of cancer with a poor prognosis that was traditionally treated with platinum-based chemotherapy. However, the recent development and approval of multiple new agents, including immune checkpoint inhibitors (ICI), a fibroblast growth factor receptor (FGFR) inhibitor, and antibody-drug conjugates (ADC) have transformed the treatment landscape for la/mUC, and these agents now play a significant role in all lines of therapy. Additionally, several phase 3 trials are investigating the combined use of ICIs and ADCs in the treatment of MIBC in hopes to improve safety and efficacy compared to the cytotoxic sledgehammer of chemotherapy.

The aim of this CME initiative is to inform learners about these new and evolving treatment options and their role in the clinical setting including:

• The latest efficacy data for ICIs, FGFRs, ADCs, and combination therapy in la/mUC

• Current NCCN guidelines for the use of novel agents and combinations for the treatment of la/mUC

• Awareness and management of treatment-related adverse events with novel agents

• Ongoing clinical trials of ADCs and their potential role in earlier lines of therapy

Please be sure to join for any or all the events listed below. Activity links will be “live” on each activity page on the program launch date. Video and tweetorial activities can be viewed live and will also be archived for later viewing on the individual activity pages linked below. Case Conversations and mini-Tweetorials can be viewed on X/Twitter by navigating to www.x.com/mondaynightibd.